{
    "clinical_study": {
        "@rank": "58669", 
        "arm_group": [
            {
                "arm_group_label": "Group 1:  12 to 17 years of age", 
                "arm_group_type": "Experimental", 
                "description": "Group 1: 100 mg Delamanid BID for 10 days"
            }, 
            {
                "arm_group_label": "Group 2:  6 - 11 years of age", 
                "arm_group_type": "Experimental", 
                "description": "50 mg Delamanid BID for 10 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to determine the pediatric dose of delamanid  that is\n      equivalent to the adult dose already shown to be effective against multidrug-resistant\n      tuberculosis."
        }, 
        "brief_title": "Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Multidrug Resistant Tuberculosis", 
            "Pediatric"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Tuberculosis", 
                "Tuberculosis, Multidrug-Resistant"
            ]
        }, 
        "detailed_description": {
            "textblock": "This trial will investigate the pharmacokinetics (PK) and safety of delamanid administered\n      twice daily for 10 days to pediatric patients aged 6 to 17 years who are also on therapy\n      with an optimized background regimen.  The purpose of the trial is to determine which dose\n      in pediatric MDR-TB patients will result in delamanid plasma exposure similar to efficacious\n      plasma exposure in adult MDR-TB patients.  This is an age de-escalation trial in two groups:\n\n      Group 1:  12 to 17 years (100 mg BID; n=6) Group 2:  6 to 11 years (50 mg BID; n =6)\n\n      Dosing of patients in Group 2 will not start until all patients in Group 1 have completed\n      the 18-day Treatment Period (10 days of dosing followed by 8 days of additional PK and\n      safety assessments)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of MDR-TB OR\n\n          -  Presumptive diagnosis of MDR TB including one of the following:\n\n               -  Persistent cough lasting > 2 weeks\n\n               -  Fever, weight loss, and failure to thrive\n\n               -  Chest radiograph consistent with TB\n\n               -  Sputum smear positive for acid-fast bacilli AND\n\n               -  Household contact of a person with known MDR TB or a person who died while\n                  appropriately taking drugs for sensitive TB/OR\n\n               -  On first-line TB treatment but with no clinical improvement\n\n          -  Negative urine pregnancy test for female patients who have reached menarche\n\n          -  Written informed consent/assent\n\n        Exclusion Criteria:\n\n          -  Positive test for HIV, previously identified as having HIV, or laboratory evidence of\n             active hepatitis B or C\n\n          -  History of allergy to metronidazole and any disease or condition in which\n             metronidazole is required\n\n          -  Use of amiodarone within 12 months or use of other predefined antiarrhythmic\n             medications within 30 days prior to first dose of delamanid\n\n          -  Serious concomitant conditions\n\n          -  Preexisting cardiac conditions\n\n          -  Abnormalities in Screening ECG (including AV block, BBB or hemi-block, QRS\n             prolongation > 120 msec, or QTcF > 450 msec in both males and females)\n\n          -  Concomitant condition such as renal impairment characterized by serum creatinine\n             levels >1.5 mg/dL, hepatic impairment (ALT or AST > 3 x ULN), or hyperbilirubinemia\n             characterized by total bilirubin > 2x ULN\n\n          -  Current diagnosis of severe malnutrition or kwashiorkor\n\n          -  Rifampicin and/or moxifloxacin within 1 week prior to the first dose of delamanid\n\n          -  Lansky Play Performance Score < 50 or Karnofsky Score < 50"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856634", 
            "org_study_id": "242-12-232"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1:  12 to 17 years of age", 
                "description": "100 mg BID for 10 days", 
                "intervention_name": "100 mg Delamanid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group 2:  6 - 11 years of age", 
                "description": "50 mg BID for 10 days", 
                "intervention_name": "50 mg Delamanid", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tuberculosis", 
            "Tuberculosis, Multidrug-Resistant", 
            "Mycobacterium Infections", 
            "Actinomycetales Infections", 
            "Gram-Positive Infections", 
            "Bacterial Infections", 
            "Pediatric"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dasmari\u00f1as City", 
                        "country": "Philippines", 
                        "state": "Cavite", 
                        "zip": "4114"
                    }, 
                    "name": "De La Salle Health Sciences Institute"
                }, 
                "investigator": [
                    {
                        "last_name": "Melchor V G Frias", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Maria P S Austria-Cantimbuhan", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Hansel J Ybanez", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Rita G Alvero", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ysterplaat", 
                        "country": "South Africa", 
                        "state": "Cape Town"
                    }, 
                    "name": "Brooklyn Chest Hospital"
                }, 
                "investigator": {
                    "last_name": "Anneke C Hesseling", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Philippines", 
                "South Africa"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs", 
        "overall_contact": {
            "email": "corey.best@otsuka-us.com", 
            "last_name": "Corey Best, MBA", 
            "phone": "919-544-8143"
        }, 
        "overall_official": {
            "affiliation": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
            "last_name": "Jeffrey Hafkin, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Plasma concentrations (Cmax, tmax, AUC0-24h, accumulation ratio, apparent terminal elimination half-life, apparent total clearance)of delamanid and its metabolites  on Days 1, 2, 10, 11, 13, 15, 18.", 
            "measure": "Plasma Concentrations", 
            "safety_issue": "No", 
            "time_frame": "Days 1, 2, 10, 11, 13, 15, 18"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856634"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of Reported Adverse Events", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "40 Days"
            }, 
            {
                "description": "Summary Statistics of subjects with clinically significant abnormal laboratory test results, vitals, EGGs", 
                "measure": "Safety Summary", 
                "safety_issue": "Yes", 
                "time_frame": "40 Days"
            }
        ], 
        "source": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}